©2014 Baishideng Publishing Group Inc.
World J Methodol. Sep 26, 2014; 4(3): 163-188
Published online Sep 26, 2014. doi: 10.5662/wjm.v4.i3.163
Published online Sep 26, 2014. doi: 10.5662/wjm.v4.i3.163
Table 4 Examples of orphan-designated drug products with marketing approvals in the United States for both common and rare disease indication
| Drug product name | Orphan indications |
| Adalimumab | Paediatric Crohn's disease |
| Aldesleukin | Primary immunodeficiency disease |
| Allopurinol | Ex vivo preservation of kidneys for transplants |
| Aminosidine | Tuberculosis and Mycobacterium avium |
| Azathioprine | Graft-vs-host disease |
| Aztreonam | Improvement of symptoms in bronchiectasis |
| Bevacizumab | Ovarian, stomach and pancreatic cancer |
| Bleomycin sulphate | Pancreatic cancer |
| Cetuximab | Pancreatic cancer |
| Cisplatin liposomal | Osteogenic sarcoma metastatic to the lung |
| Colchicine | Behcet's Syndrome |
| L-Cycloserine | Gaucher's disease |
| Cyclosporine | Prophylaxis and treatment of GVH disease |
| Cyclosporine A implant | Prevention of rejection in cornea transplant |
| Cyclosporine liposomal | Bronchiolitis obliterans |
| Doxorubicin | Hepatocellular carcinoma |
| Doxorubicin HCl liposomal | Soft tissue sarcomas |
| Doxorubicin nanoparticles | Hepatocellular carcinoma |
| Eflornithine HCl | Pneumocystis carinii pneumonia in AIDS |
| Epoetin alpha | Myelodysplastic syndrome |
| Erlotinib HCl | Malignant gliomas |
| Etidronate disodium | Degenerative metabolic bone disease |
| Everolimus | Gastroenteropancreatic tumors |
| Histrelin | Acute intermittent and other porphyries |
| Immuneglobulin | Juvenile rheumatoid arthritis |
| Infliximab | Chronic sarcoidosis |
| Interferon alfa-2a | Esophageal carcinoma |
| Peginterferon alfa-2a | Chronic myelogenous leukemia |
| Interferon alfa-2b | Ovarian carcinoma, brain tumors |
| Peginterferon alfa-2b | Chronic delta hepatitis |
| Metronidazole (topical) | Perioral dermatitis |
| Metronidazole | Pouchitis |
| N-acetylcysteine | Acute liver failure |
| Paclitaxel | Pancreatic cancer |
| Paclitaxel aqueous gel | Esophageal and brain cancer |
| Paclitaxel micellar | Ovarian cancer |
| Paclitaxel protein-bound | Stage IIB to IV melanoma |
| Sorafenib | Stage IIB through stage IV melanoma |
| Ribavirin | Haemorrhagic fever with renal syndrome |
| Rituximab | Immune thrombocytopenic purpura |
| Thiotepa | Haematopoietic stem cell transplantation |
| Tranexamic acid | Hereditary angioneurotic edema |
| Urofollitropin | Initiation and re-initiation of spermatogenesis |
| Ursodiol | Cystic fibrosis liver disease |
- Citation: Kontoghiorghe CN, Andreou N, Constantinou K, Kontoghiorghes GJ. World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients. World J Methodol 2014; 4(3): 163-188
- URL: https://www.wjgnet.com/2222-0682/full/v4/i3/163.htm
- DOI: https://dx.doi.org/10.5662/wjm.v4.i3.163